CAR-T在治疗恶性胸膜间皮瘤中的研究进展  

Research progress on application of CAR-T in treatment of malignant pleural mesothelioma

作　　者：杨侃[1] 胡文滕 韩彪[1] Yang Kan;Hu Wenteng;Han Biao(Department of Thoracic Surgery,the First Hospital of Lanzhou University,Lanzhou 730000,China)

机构地区：[1]兰州大学第一医院胸外科,兰州730000

出　　处：《新医学》2021年第12期903-906,共4页Journal of New Medicine

基　　金：甘肃省青年科技基金计划(18JR3RA305)。

摘　　要：恶性胸膜间皮瘤(MPM)是一种具有高度侵袭性的多与石棉接触有关的胸膜疾病。MPM的局部高侵袭性导致其治疗方法的选择有限,虽然手术治疗及化学治疗药物方面的研究进展延长了部分MPM患者的生存期,但是MPM总体生存期仍低,目前仍无新的治疗方法可以改善MPM患者的结局。嵌合抗原受体(CAR)是通过现代分子生物技术构建的融合蛋白,嵌合抗原受体T细胞(CAR-T)疗法在治疗血液系统恶性肿瘤中已获较满意疗效,部分试验证实了CAR-T应用于实体肿瘤的安全性及有效性,该文就CAR-T在治疗MPM中的研究进展做一综述。Malignant pleural mesothelioma(MPM) is a highly aggressive pleural disease, which is mainly associated with asbestos contact. Due to the locally aggressive nature of MPM, treatment options are limited. Although the survival of partial MPM patients has been prolonged by surgical treatment and chemotherapeutic drugs, the overall survival of MPM patients remains poor and there is still no new treatment to improve the outcomes of MPM patients. Chimeric antigen receptor(CAR) is a fusion protein constructed by modern molecular biotechnology. Satisfactory clinical efficacy of CAR-T cell(CAR-T) therapy has been obtained in hematologic malignancies. Multiple experiments have confirmed the safety and efficacy of CAR-T in solid tumors. This article reviews the research progress on the application of CAR-T in MPM.

关 键 词：恶性胸膜间皮瘤 嵌合抗原受体 嵌合抗原受体T细胞 

分 类 号：R734.3[医药卫生—肿瘤]